Summary
Considerable research has been aimed at improving the efficacy of chemotherapeutic agents for cancer therapy. A promising two-step approach that is designed to minimize systemic drug toxicity while maximizing activity in tumours employs monoclonal antibody (mAb)–enzyme conjugates for the activation of anticancer prodrugs. We present, analyse and numerically simulate a mathematical model based on the biology of the system to study the biodistribution, pharmacokinetics and localization properties of mAb–enzyme conjugates in tumour tissue. The model predictions were compared with experimental observations and an excellent correlation was found to exist. In addition, the critical parameters affecting conjugate half-life were determined to be the inter-capillary half-distance and the antibody–antigen binding affinity. An approximation is presented relating the per cent injected dose per gram to inter-capillary half-distance and time. Finally, the model was used to examine various dosing strategies in an attempt to determine which regimen would provide the best biodistribution results. We compared the results of administering a uniform dose of fusion protein via bolus injection, multiple injections and continuous infusion. The model predicts that dosing strategy has little effect on the amount of conjugate that localizes in the tumour.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bagshawe, K. D. & Begent, R. H. J. (1996). First clinical experience with ADEPT. Adv Drug Delivery Rev 22: 365–367.
Baxter, L. T. & Jain, R. K. (1989). Transport of fluid and macromolecules in tumors. I. role of interstitial pressure and convection. Microvasc Res 37: 77–104.
Baxter, L. T. & Jain, R. K. (1991a). Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 41: 5–23.
Baxter, L. T. & Jain, R. K. (1991b). Transport of fluid and macromolecules in tumors. IV. a microscopic model of the perivascular distribution. Microvasc Res 41: 252–272.
Baxter, L. T. & Jain, R. K. (1996). Pharmacokinetics analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 73: 447–456.
Baxter, L. T., Yuan, F. & Jain, R. K. (1992). Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 52: 5838–5844.
Bosslet, K., Czech, J. & Hoffmann, D. (1994). Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54: 2151–2159.
Eccles, S. A., Court, W. J., Box, G. A., Dean, C. J., Melton, G. R. & Springer, C. J. (1994). Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erb-b2 p185. Cancer Res 54: 5171–5177.
Gerlowski, L. E. & Jain, R. K. (1986). Microvascular permeability of normal and neoplastic tissues. Microvas Res 31: 288–305.
Kerr, D. E., Schreiber, G. J., Vrudhula, B. M., Svensson, H. P., Hellstrom, K. E. & Senter, P. D. (1995). Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 55: 3558–3563.
Krogh, A. (1919). The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J of Physiol 52: 409–415.
Melton, R. G. & Sherwood, R. F. (1996). Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 88: 153–165.
Meyer, D. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L. & Starling, J. J. (1992). Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long term growth inhibition of human colon carcinoma xenograft models. Cancer Res 53: 3956–3963.
Niculescu-Duvaz, I. & Springer, C. J. (1996). Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr Med Chem 2: 687–706.
Nugent, L. J. & Jain, R. K. (1984). Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238–244.
O’Callaghan, D. E., Morris, A., Kirby, S. & Shingler, A. H. (1972). Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1: 283–288.
Pietersz, G. A., Rowland, A., Smyth, M. J. & McKenzie, I. F. (1994). Chemoimmunoconjugates for the treatment of cancer. Adv Immunol 56: 301–387.
Senter, P. D. & Svensson, H. P. (1997). A summary of monoclonal antibody–enzyme/prodrug combinations. Adv Drug Delivery Rev 22: 341–349.
Senter, P. D., Wallace, P. M., Svensson, H. P., Vrudhula, V. M., Kerr, D. E., Hellstrom, I. & Hellstrom, K. E. (1993). Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem 4: 3–9.
Siemers, N. O., Kerr, D. E., Yarnold, S., Stebbins, M., Vrudhula, V. M., Hellstrom, I., Hellstrom, K. E. & Senter, P. D. (1997). L49-sfv-β-lactamase, a single chain anti-p97 antibody fusion protein. Bioconjugate Chem 8: 510–519.
Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, P. J., Rogers, G. T., Sherwood, R. F. & Melton, R. G. (1991). Abalation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361–1366.
Svensson, H. P., Vrudhula, V. M., Emswiler, J. E., MacMaster, J. F., Cosand, W. L., Wallace, P. M. & Senter, P. D. (1995). In vitro and in vivo activities of doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res 55: 2357–2365.
Wallace, P. M., MacMaster, J. F., Smith, V., Kerr, D. E., Senter, P. D. & Cosand, W. L. (1994). Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719–2723.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jackson, T., Lubkin, S., Siemers, N. et al. Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates. Br J Cancer 80, 1747–1753 (1999). https://doi.org/10.1038/sj.bjc.6690592
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690592